228 related articles for article (PubMed ID: 24939104)
1. Synthesis and biological evaluation of new pyrimidine-4-yl-ethanol derivatives as ROS1 kinase inhibitors.
Abdelazem AZ; Lee SH
J Enzyme Inhib Med Chem; 2015 Apr; 30(2):290-8. PubMed ID: 24939104
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of new pyrazol-4-ylpyrimidine derivatives as potential ROS1 kinase inhibitors.
Abdelazem AZ; Al-Sanea MM; Park BS; Park HM; Yoo KH; Sim T; Park JB; Lee SH; Lee SH
Eur J Med Chem; 2015 Jan; 90():195-208. PubMed ID: 25461320
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of new potent and highly selective ROS1-tyrosine kinase inhibitor.
Park BS; El-Deeb IM; Yoo KH; Oh CH; Cho SJ; Han DK; Lee HS; Lee JY; Lee SH
Bioorg Med Chem Lett; 2009 Aug; 19(16):4720-3. PubMed ID: 19596575
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R.
Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X
Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, biological evaluation and molecular modeling of novel 2-amino-4-(1-phenylethoxy) pyridine derivatives as potential ROS1 inhibitors.
Tian Y; Zhang T; Long L; Li Z; Wan S; Wang G; Yu Y; Hou J; Wu X; Zhang J
Eur J Med Chem; 2018 Jan; 143():182-199. PubMed ID: 29174814
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, screening, and molecular modeling study of a new series of ROS1 receptor tyrosine kinase inhibitors.
El-Deeb IM; Park BS; Jung SJ; Yoo KH; Oh CH; Cho SJ; Han DK; Lee JY; Lee SH
Bioorg Med Chem Lett; 2009 Oct; 19(19):5622-6. PubMed ID: 19700314
[TBL] [Abstract][Full Text] [Related]
7. Structure-based optimization and biological evaluation of trisubstituted pyrazole as a core structure of potent ROS1 kinase inhibitors.
Park BS; Al-Sanea MM; Abdelazem AZ; Park HM; Roh EJ; Park HM; Yoo KH; Sim T; Tae JS; Lee SH
Bioorg Med Chem; 2014 Aug; 22(15):3871-8. PubMed ID: 24997577
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of novel 4-arylaminopyrimidine derivatives possessing a hydrazone moiety as dual inhibitors of L1196M ALK and ROS1.
Wang Y; Zhang G; Hu G; Bu Y; Lei H; Zuo D; Han M; Zhai X; Gong P
Eur J Med Chem; 2016 Nov; 123():80-89. PubMed ID: 27474925
[TBL] [Abstract][Full Text] [Related]
9. Fragment-based modification of 2,4-diarylaminopyrimidine derivatives as ALK and ROS1 dual inhibitors to overcome secondary mutants.
Zhu M; Li W; Zhao T; Chen Y; Li T; Wei S; Guo M; Zhai X
Bioorg Med Chem; 2020 Oct; 28(20):115719. PubMed ID: 33069075
[TBL] [Abstract][Full Text] [Related]
10. Design, Synthesis and Biological Evaluation of Some 5-Arylthieno[2,3-d]pyrimidines as Potential Anti-cancer Agents.
El-Ansary AK; Kamal AM; Al-Ghorafi MA
Chem Pharm Bull (Tokyo); 2016; 64(8):1172-80. PubMed ID: 27477657
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of N-phenylthieno[2,3-d]pyrimidin-4-amines as inhibitors of FGFR1.
Gryshchenko AA; Bdzhola VG; Balanda AO; Briukhovetska NV; Kotey IM; Golub AG; Ruban TP; Lukash LL; Yarmoluk SM
Bioorg Med Chem; 2015 May; 23(9):2287-93. PubMed ID: 25817240
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of a triazole-based library of pyrido[2,3-d]pyrimidines as FGFR3 tyrosine kinase inhibitors.
Le Corre L; Girard AL; Aubertin J; Radvanyi F; Benoist-Lasselin C; Jonquoy A; Mugniery E; Legeai-Mallet L; Busca P; Le Merrer Y
Org Biomol Chem; 2010 May; 8(9):2164-73. PubMed ID: 20401393
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of cyclin D1-CDK4: synthesis, biological evaluation and structure-activity relationships. Part 2.
Horiuchi T; Nagata M; Kitagawa M; Akahane K; Uoto K
Bioorg Med Chem; 2009 Dec; 17(23):7850-60. PubMed ID: 19889545
[TBL] [Abstract][Full Text] [Related]
14. Structure-based optimization identified novel furyl-containing 2,4-diarylaminopyrimidine analogues as ALK/ROS1 dual inhibitors with anti-mutation effects.
Guo M; Zuo D; Zhao T; Li X; Cao J; Qiu Y; Wei S; Zhai X
Eur J Med Chem; 2021 Mar; 214():113259. PubMed ID: 33581554
[TBL] [Abstract][Full Text] [Related]
15. An exploration of solvent-front region high affinity moiety leading to novel potent ALK & ROS1 dual inhibitors with mutant-combating effects.
Lei H; Jia F; Cao M; Wang J; Guo M; Zhu M; Zuo D; Zhai X
Bioorg Med Chem; 2019 Oct; 27(20):115051. PubMed ID: 31492532
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and SAR of 2-phenoxypyridines as novel c-Jun N-terminal kinase inhibitors.
Song X; Chen W; Lin L; Ruiz CH; Cameron MD; Duckett DR; Kamenecka TM
Bioorg Med Chem Lett; 2011 Dec; 21(23):7072-5. PubMed ID: 22004719
[TBL] [Abstract][Full Text] [Related]
17. Discovery and SAR of novel 4-thiazolyl-2-phenylaminopyrimidines as potent inhibitors of spleen tyrosine kinase (SYK).
Farmer LJ; Bemis G; Britt SD; Cochran J; Connors M; Harrington EM; Hoock T; Markland W; Nanthakumar S; Taslimi P; Ter Haar E; Wang J; Zhaveri D; Salituro FG
Bioorg Med Chem Lett; 2008 Dec; 18(23):6231-5. PubMed ID: 18938080
[TBL] [Abstract][Full Text] [Related]
18. Part-1: Design, synthesis and biological evaluation of novel bromo-pyrimidine analogs as tyrosine kinase inhibitors.
Munikrishnappa CS; Puranik SB; Kumar GV; Prasad YR
Eur J Med Chem; 2016 Aug; 119():70-82. PubMed ID: 27155464
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of Cyclin D1-CDK4: synthesis, biological evaluation, and structure-activity relationships.
Horiuchi T; Chiba J; Uoto K; Soga T
Bioorg Med Chem Lett; 2009 Jan; 19(2):305-8. PubMed ID: 19091560
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of benzyl 2-(1H-imidazole-1-yl) pyrimidine analogues as selective and potent Raf inhibitors.
Kim M; Lee J; Jung K; Kim H; Aman W; Ryu JS; Hah JM
Bioorg Med Chem Lett; 2014 Aug; 24(15):3600-4. PubMed ID: 24878193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
